title: Interferon Inducible IFI16 Expression in p16 Positive Squamous Cell Carcinoma of the Oropharynx.
abstract: Human-papillomavirus- (HPV-) positive oropharyngeal squamous cell carcinomas (OPSCC) are reported to be more responsive to treatment and to be related to a favorable prognosis compared with non-HPV carcinomas. However, the molecular basis of the responsiveness is unclear. Interferon inducible IFI16, which is implicated in the control of cell growth, apoptosis, angiogenesis, and immunomodulation in various types of cancers, is reported to be frequently expressed in the HPV-positive head and neck SCC and to correlate with a better prognosis. In this study, we hypothesized that HPV related OPSCC expresses IFI16 resulting in favorable prognosis. To clarify the relationship between the prognosis of HPV related OPSCC patients and IFI16 status, we examined immunohistologically the pretreatment specimens of OPSCC for the expression of p16 as a surrogate marker of HPV infection and IFI16. We could not show that the expression of IFI16 is associated with that of p16. There was no significant difference in the survival rate between IFI16 positive and negative groups. Patients with p16 negative tumor exhibited worse survival rate regardless of IFI16 status. In this limited case series, we could not conclude that IFI16 expression is altered in p16 positive OPSCC and that it would be a new predictive marker or a useful therapeutic tool.
authors: Department of Otorhinolaryngology, Head and Neck Surgery, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan.
authors: Moriyasu
authors: M
authors: Yamauchi
authors: Takafumi
authors: T
authors: Nakano
authors: Torahiko
authors: T
authors: Nakashima
authors: Ryuji
authors: R
authors: Yasumatsu
authors: Kazuki
authors: K
authors: Hashimoto
authors: Satoshi
authors: S
authors: Toh
authors: Hideki
authors: H
authors: Shiratsuchi
authors: Yoshinao
authors: Y
authors: Oda
authors: Shizuo
authors: S
authors: Komune
references: J Biol Chem. 2003 Oct 17;278(42):40899-904
references: 12925527
references: Clin Cancer Res. 2009 Nov 15;15(22):6758-62
references: 19861444
references: Oncogene. 2000 Dec 7;19(52):6033-42
references: 11146555
references: Lancet Oncol. 2010 Aug;11(8):781-9
references: 20451455
references: Oncogene. 2002 Feb 28;21(10):1510-7
references: 11896579
references: Cancer. 2010 May 1;116(9):2166-73
references: 20186832
references: Auris Nasus Larynx. 2011 Jun;38(3):387-91
references: 21035287
references: Exp Cell Res. 2004 Feb 15;293(2):331-45
references: 14729471
references: Mol Cell Biol. 1999 Sep;19(9):5833-8
references: 10454530
references: Histopathology. 2004 Dec;45(6):560-72
references: 15569046
references: Adv Otorhinolaryngol. 2005;62:72-80
references: 15608419
references: Oncogene. 2003 Jul 31;22(31):4831-40
references: 12894224
references: N Engl J Med. 2010 Jul 1;363(1):24-35
references: 20530316
references: Mol Immunol. 2012 Jan;49(4):567-71
references: 22137500
references: Br J Cancer. 2010 Nov 9;103(10):1510-7
references: 20959828